Osivax Company
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Technology:
Atrificial Vectors and Immune Cells
Industry:
Atrificial Vectors and Immune Cells
Headquarters:
Lyon, Rhone-Alpes, France
Founded Date:
2017-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
5
Total Funding:
46143932
Estimated Revenue:
$1M to $10M
Last Funding Date:
2020-07-08
Last Funding Type:
Grant
Register and Claim Ownership